

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Signature

Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: Arindam Chatterjee

Group Art Unit: 4161

Serial No.: 10/535,061

Examiner:
Valerie Rodriguez-Garcia

Filing Date: May 12, 2005

Conf No.: 9394

For: Mixed Lineage Kinase Modulators

Docket No.: X15649

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

This response addresses the Office communication provided on May 13, 2008 wherein the present application was subjected to a restriction requirement.

Applicants make a provisional election and submit the following remarks.

The Office indicates that restriction is required under 35 U.S.C. 121 and 372. The following groups are provided by the Office:

Group I, Claims 5-13, drawn to compounds and compositions reading on Formula 1 claim 5.

Group II, Claim 14, drawn to a method of treating congestive heart failure limited in scope to one of the compounds of group I.

Applicants are required under 37 CFR § 1.143 to make a provisional election. Applicants provisionally elect Group I. Applicants also provisionally elect the species provided in Example 78, which is 2-fluoro-4-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]phenylamine Ditrifluoroacetic Acid, in the specification as filed. The provisional election encompasses Claims 5 through 13. Example 78 is within the scope of Claims 5 through 10 and 13.